As a science-led global healthcare company, GlaxoSmithKline (GSK) has the opportunity to improve the health and well-being of millions of people around the world. We want to help people live healthy lives regardless of where they live or their ability to pay. GSK is playing an important role in addressing the health challenges of the developing world through innovative partnerships in wide-ranging areas such as R&D, disease elimination programmes, new business models, community partnerships, voluntary licensing and increasing the affordability of our products1.
As we approach the expiration of the Millennium Development Goals (MDGs) in 2015, it is clear that the setting of clear goals has proven a successful strategy to drive progress, on a defined set of issues that posed the greatest challenge to poverty reduction and human development. The MDGs were simple and measurable as well as broadly understood by all development stakeholders, including the private sector. In some countries, some MDGs have been met ahead of schedule, whilst other countries are not likely to reach the targets by 2015. It is critical that we do not lose sight of completing the MDGs between now and 2015, but it is also essential that we begin to contemplate the next generation of the development framework.
Read more at Global Public Policy Issues
